Posts

Medicinal marijuana for epilepsy: a case series study.

Authors: Lady Diana Ladino, Lizbeth Hernández-Ronquillo, José Francisco Téllez-Zenteno
Canadian Journal of Neurological Sciences, November 2014

OBJECTIVE: To describe the social, clinical and use-patterns characteristics of medicinal marijuana use among patients with epilepsy (PWEs). METHODS: Eighteen PWEs with prescriptions for medicinal marijuana from a Canadian adult-epilepsy clinic were included in this study. RES…

Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB 2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.

Authors: Magdalena Florek-Luszczki, Aleksandra Wlaz, Maria W. Kondrat-Wrobel, et al
Journal of Neural Transmission, July 2014

The aim of this study was to characterize the influence of WIN 55,212-2 (WIN–a non-selective cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant effects of various classical antiepileptic drugs (clobazam, clonazepam, phenobarbital and valproate) in the mouse 6 Hz-…

The case for medical marijuana in epilepsy.

Authors: Edward Maa, Paige Figi
Epilepsia, June 2014

Charlotte, a little girl with SCN1A-confirmed Dravet syndrome, was recently featured in a special that aired on CNN. Through exhaustive personal research and assistance from a Colorado-based medical marijuana group (Realm of Caring), Charlotte’s mother started adjunctive thera…

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Authors: Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez‐Ruiz, et al
Epilepsia, June 2014

To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant…

The case for assessing cannabidiol in epilepsy

Authors: Maria Roberta Cilio, Elizabeth A. Thiele, Orrin Devinsky
Epilepsia, June 2014

Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the ma…

Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders.

Authors: Barbara S. Koppel, John C.M. Brust, Terry Fife, Jeff Bronstein, Sarah Youssof, et al
Neurology, 29 April 2014

OBJECTIVE: To determine the efficacy of medical marijuana in several neurologic conditions. METHODS: We performed a systematic review of medical marijuana (1948-November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We gra…

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.

Authors: Itay Lotan, Therese Treves, Yaniv Roditi, Ruth Djaldetti
Clinical Neuropharmacology, March-April 2014

OBJECTIVE: The use of cannabis as a therapeutic agent for various medical conditions has been well documented. However, clinical trials in patients with Parkinson disease (PD) have yielded conflicting results. The aim of the present open-label observational study was to assess…

Cannabinoids for epilepsy.

Authors: David Gloss, Barbara Vickrey
Cochrane Database of Systematic Reviews, 5 March 2014

BACKGROUND: Marijuana appears to have anti-epileptic effects in animals. It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly approved its use for epilepsy. OBJECTIVES: To assess the efficacy and sa…

Association between pre- and perinatal exposures and Tourette syndrome or chronic tic disorder in the ALSPAC cohort.

Authors: Carol A. Mathews, Jeremiah M. Scharf, Laura L. Miller, Corrie Macdonald-Wallis, et al
British Journal of Psychiatry, January 2014

BACKGROUND: Tourette syndrome and chronic tic disorder are heritable but aetiologically complex. Although environment plays a role in their development, existing studies of non-genetic risk factors are inconsistent. AIMS:
To examine the association between pre- and perinatal e…

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Authors: Brenda E. Porter, Catherine Jacobson
Epilepsy & Behavior, December 2013

Severe childhood epilepsies are characterized by frequent seizures, neurodevelopmental delays, and impaired quality of life. In these treatment-resistant epilepsies, families often seek alternative treatments. This survey explored the use of cannabidiol-enriched cannabis in ch…

Cannabinoids: well-suited candidates for the treatment of perinatal brain injury.

Authors: David Fernández-López, Ignacio Lizasoain, Maria Ángeles Moro, José Martínez-Orgado
Brain Sciences, 10 July 2013

Perinatal brain injury can be induced by a number of different damaging events occurring during or shortly after birth, including neonatal asphyxia, neonatal hypoxia-ischemia and stroke-induced focal ischemia. Typical manifestations of these conditions are the presence of glut…

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors: Javier Fernández‐Ruiz, Onintza Sagredo, M. Ruth Pazos, Concepción García, Roger Pertwee, et al
British Journal of Clinical Pharmacology, February 2013

Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous disorders exerted through molecular mechanisms that are yet to be completely identified. CBD acts in some experimental models as an anti-inflammatory, anticonvulsant, anti-oxidant, anti-emetic, an…